At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Amicus Therapeutics is a biopharmaceutical company developing next-generation treatments for a broad range of human genetic diseases, with a focus on improving therapies for lysosomal storage diseases.
More...
NEWS
01/26/2015 Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium
01/12/2015 Amicus Therapeutics Provides Full-Year 2015 Strategic Outlook and Financial Guidance
01/08/2015 Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study
More...
Amicus Therapeutics CEO: Driving science to a cure
John Crowley, Amicus Therapeutics chairman and CEO, discusses its Fabry pill development and next generation therapy for Pompe disease, with CNBC's Jim Cramer.



Click Here to Read the Article

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy